GAMMA Investing’s Maravai LifeSciences MRVI Stock Holding History

GAMMA Investing’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.93K	Buy	1,166 +282	+32%	+$1.95K	﹤0.01%	3408
2026 Q2	$5.52K	Buy	884 +52	+6%	+$224	﹤0.01%	3424
2026 Q1	$2.36K	Buy	832 +687	+474%	+$2.33K	﹤0.01%	3619
2025 Q4	$471	Buy	+145	New	+$488	﹤0.01%	3923
2025 Q1	–	Sell	-2,774	Closed	-$15.1K	–	3854
2024 Q4	$15.1K	Buy	2,774 +593	+27%	+$3.82K	﹤0.01%	2408
2024 Q3	$18.1K	Sell	2,181 -1,404	-39%	-$12.1K	﹤0.01%	2164
2024 Q2	$25.7K	Buy	3,585 +2,711	+310%	+$23.4K	﹤0.01%	1680
2024 Q1	$7.58K	Buy	874 +825	+1,684%	+$5.58K	﹤0.01%	2201
2023 Q4	$284	Buy	+49	New	+$317	﹤0.01%	3079

Other funds holding MRVI

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

GAMMA Investing's MRVI Position: Q3 2026 in Review

GAMMA Investing increased its Maravai LifeSciences (MRVI) stake by 32% in Q3 2026, buying an estimated $1.95K and bringing the position to 1,166 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

GAMMA Investing first reported a position in MRVI in Q4 2023 and has held it in 9 quarters since. The position peaked at $25.7K in Q2 2024. 60 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

GAMMA Investing held 1,166 shares of Maravai LifeSciences worth $8.93K as of Q3 2026.
GAMMA Investing bought 282 Maravai LifeSciences shares in Q3 2026, an estimated $1.95K.
Maravai LifeSciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3408 holding.
GAMMA Investing first reported a position in Maravai LifeSciences in Q4 2023 and has held it in 9 quarters since.
GAMMA Investing's Maravai LifeSciences position peaked at $25.7K in Q2 2024.
60 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.